PRRT2 and neuroblastoma: Our attempts at pharmacologic upregulation of GD2 in OS by the use of PKC modulators, effective to enhance expression of CD22 in B‐cell malignancies25, 34 and gangliosides in neuroblastoma,26 were also unsuccessful.